Fierce Medtech names Paige as one of its “Fierce 15” companies of 2020
08 März 2021 - 3:15PM
Business Wire
Paige, a global leader in AI-based diagnostic software in
pathology, today announced that it has been named by Fierce Medtech
as one of 2020’s Fierce 15, designating it as one of the most
promising private companies in the industry.
“We are honored to be named as one of the Fierce 15 companies of
2020, which is a testament to our team’s innovation, creativity and
perseverance even in the face of intense competition and a global
pandemic,” said Leo Grady, Ph.D., Chief Executive Officer, Paige.
“Paige sits among the most innovative medical technology companies
at a time of rapid innovation in the broader healthcare space. We
are excited to grow and expand our team this year as we build a
transformational portfolio of computational pathology products to
serve clinical needs and drive precision medicine.”
In the past year, Paige raised more than $100 million to
transform and grow the Company’s portfolio of digital and
computational pathology products for cancer while securing FDA
clearance for its FullFocus™ digital pathology image viewer in the
U.S. and achieving CE marks for its Paige Prostate and Paige Breast
diagnostic software.
“Each member of this year’s class of Fierce 15 stands out in a
different way, but they all overcame a year of unforgettable
obstacles, making each of their successes that much more
significant — and all have the potential to deliver changes in
healthcare that promise to outlast this pandemic,” said Conor Hale,
associate editor of Fierce Medtech.
An internationally recognized daily report reaching a network of
over 90,000 med tech industry professionals, Fierce Medtech
provides subscribers with an authoritative analysis of the day's
top stories. Every year Fierce Medtech evaluates hundreds of
private companies from around the world for its annual Fierce 15
list, which is based on a variety of factors such as the strength
of its technology, partnerships, venture backers and a competitive
market position.
The full list of winners can be viewed online here.
About Paige Paige was founded in 2017 by Thomas Fuchs,
Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center
(MSK). The company builds computational pathology products designed
so patients and their care teams can make effective, more informed
treatment decisions. With this new class of AI-based technologies
positioned to drive the future of diagnostics, Paige created a
platform to deliver this novel technology to pathologists to
transform their workflow and increase diagnostic confidence and
productivity. Paige’s products deliver insights to pathologists and
oncologists so they can arrive efficiently at more precise
diagnoses for patients. Paige is the first company to receive FDA
breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai,
https://www.paigeplatform.com, Twitter and LinkedIn.
About Fierce Medtech Fierce Medtech keeps biopharma
executives, device developers, engineers, and researchers updated
on the must-know news, trends and developments in medical
technology. More than 90,000 top industry professionals rely on
Fierce Medtech for an insider briefing on the day's top
stories.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210308005243/en/
Jon Yu Westwicke/ICR Healthcare PR Tel: 475.395.5375
Jon.Yu@westwicke.com
Rebecca Willumson Fierce Medtech 202-824-5050
rwillumson@questex.com